Asset Search & Evaluation

A large, global pharmaceutical company engaged Blue Matter to help identify late-stage CNS assets for potential in-licensing or acquisition to drive the inorganic growth of the company.

Our team started by understanding the strategy for the business unit and the core capabilities and expertise of the client. We then developed filtering criteria (e.g., phase of development, geography, etc.,) for the search. We then built a robust asset database, combining multiple data sources and additional secondary research to complement our strong internal databases. Next, we aligned with the team on more detailed filtering criteria (e.g., specific indications of focus, opportunity size, etc.) to shortlist a set of assets for further analysis. We synthesized detailed profiles for each shortlisted asset, scoring them using an asset prioritization framework that considered scientific/clinical, commercial, financial, and strategic criteria. Finally, we worked with the cross-functional client team to refine our prioritization, then shared our recommendations regarding specific assets to pursue.

We delivered a robust asset scan that considered strategic, clinical, commercial and financial factors to identify and prioritize a set of attractive assets that the client could pursue for acquisitions.